<DOC>
	<DOCNO>NCT02227914</DOCNO>
	<brief_summary>The purpose Phase 1b study determine maximum tolerate dose , pharmacokinetics ( PK ) pharmacodynamics ( PDn ) ass safety , tolerability activity oprozomib combination sorafenib subject advance hepatocellular carcinoma ( HCC ) . The purpose Phase 2 study evaluate efficacy oprozomib combination sorafenib versus sorafenib alone compare key outcome measure subject advance HCC .</brief_summary>
	<brief_title>Phase 1b/2 Study Oprozomib Combination With Sorafenib Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Key 1 . Patients advance HCC 2 . For Phase 2 portion study , least 1 measurable tumor lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 , previously treat local therapy 3 . Cirrhotic status ChildPugh Class A 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 5 . The following laboratory parameter : Albumin ≥ 2.8 g/dL Platelet count ≥ 60,000/mm3 Absolute neutrophil count ( ANC ) ≥ 1500/mm3 Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 3 mg/dL Alanine aminotransaminase ( ALT ) aspartate aminotransferase ( AST ) ≤ 3 time upper limit normal ( ULN ) Amylase lipase ≤ 1.5 time ULN Calculated measure creatinine clearance ( CrCl ) ≥ 30 mL/min Prothrombin time ( PT ) international normalize ratio ( INR ) ≤ 2.3 PT ≤ 6 second control Key 1 . Previous concurrent cancer distinct primary site histology HCC , EXCEPT cervical breast carcinoma situ , adequately treat basal cell squamous cell carcinoma skin , superficial bladder tumor ( Ta , Tis &amp; T1 ) 2 . Renal failure require hemo peritoneal dialysis 3 . History cardiac disease 4 . Active clinically serious infection . Hepatitis B allow active replication present . Hepatitis C allow antiviral treatment require 5 . Known history human immunodeficiency virus ( HIV ) infection 6 . Known history symptomatic metastatic brain meningeal tumor 7 . Clinically significant gastrointestinal ( GI ) bleeding , serious nonhealing wound ulcer within 3 month prior study entry , bone fracture within 30 day prior study entry 8 . History organ allograft 9 . Known suspected allergy investigational agent agent give association trial 10 . Inability swallow medication , inability unwillingness comply drug administration requirement , GI condition could interfere oral absorption tolerance treatment 11 . Uncontrolled diabetes 12 . Any contraindication oral hydration ( e.g. , preexist cardiac impairment fluid restriction ) 13 . Uncontrolled ascites 14 . Pleural effusion ascites cause respiratory compromise ( NCICTCAE ≥ Grade 2 dyspnea ) . 15 . Women pregnant and/or breastfeed 16 . Prior use systemic anticancer chemotherapy HCC 17 . Prior use systemic investigational agent HCC 18 . Concomitant treatment strong cytochrome P450 3A4 ( CYP3A4 ) inhibitors 19 . Known hypersensitivity intolerance dexamethasone 5HT3 antagonist</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>